We are currently making some changes to how orders are placed and because of this there will be a
short disruption period affecting order processing. Thank you for your patience while we work to
operate as smoothly as possible (November 14, 2023).
UKKi018-A
NP0080-2B
iPSC line
Purchases have been temporarily disabled, as we are transitioning sales and distribution.
If you are interested in purchasing this cell line, please contact EBiSC directly. For more information about the current transition process see here.
If you are interested in purchasing this cell line, please contact EBiSC directly. For more information about the current transition process see here.
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg Name | UKKi018-A |
| Alternative name(s) |
NP0080-2B
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UKKi035-B (NP0139-B, NP0139-6C) Donor's gene variants: MYBPC3, MYBPC3 Donor diseases: Rare hypertrophic cardiomyopathy |
Provider |
|
| Depositor | Klinikum der Universität zu Köln (UKK) |
| Owner | Institute for Neurophysiology, Medical Faculty |
| Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
| Derivation country | Germany |
External Databases |
|
| hPSCreg | UKKi018-A |
| BioSamples | SAMEA17622418 |
| Cellosaurus | CVCL_LD25 |
| CLO | CLO_0101618 |
| Wikidata | Q54990438 |
General Information |
|
| Publications | View all related publications on hPSCreg (1) |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 20-24 |
| Ethnicity | caucasian / european |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Is the medical history available upon request? | yes |
| Is clinical information available? | yes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA17623168 |
hIPSC Derivation#
General |
|
| Source cell type |
peripheral blood mononuclear cellA leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
|
| Age of donor (at collection) | 20-24 |
| Collected in | 2016 |
| Source cell line vendor | University Hospital Münster, Germany |
| Passage number reprogrammed | 0 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
Immunostaining, PCR
|
| Notes on reprogramming vector detection | sendai virus absent |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | morphology |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
Latest released batch |
|
| Culture medium | mTeSR1 |
| Passage method | EDTA |
| Surface coating | Matrigel |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 °C |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Vitronectin | |||||||||
| Feeder cells |
No |
|||||||||
| Passage method |
Enzyme-free cell dissociation
EDTA
|
|||||||||
| O2 Concentration | 20 % | |||||||||
| CO2 Concentration | 5 % | |||||||||
| Medium |
Essential 8™
Supplements
|
|||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
|||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
|||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
Morphology pictures
morphology pictures of iPS cell line NP0080-2B before banking and of the thawing control
morphology pictures of iPS cell line NP0080-2B before banking and of the thawing control
morphology pictures of iPS cell line NP0080-2B before banking and of the thawing control
Differentiation Potency
In vitro directed differentiation
Morphology
expression of SOX17 in differentiated iPS cell line NP0080-2B
In vitro directed differentiation
Morphology
expression of BRACHYURY in differentiated iPS cell line NP0080-2B
In vitro directed differentiation
Morphology
expression of NESTIN in differentiated iPS cell line NP0080-2B
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
No larger chromosomal aberrations observed
Passage number: 33
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
|